In an animal model, Yoshiji et al. reported that angiotensin II progressed hepatic fibrosis in NAFLD rats, and the angiotensin-converting enzyme inhibitor decreased tumor growth by suppressing the endothelial vascular growth factor [24]. Opinions regarding the relationship between triglycerides and hepatocellular carcinoma vary, and no clear consensus has been reached. This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatotic liver disease.